Genomics

Dataset Information

0

ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

ABSTRACT: ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

PROVIDER: PRJNA627126 | ENA |

REPOSITORIES: ENA

Json Xml

Dataset's files

Source:
Action DRS
SRR11579382.fastq.gz Fastqsanger.gz
SRR11579383.fastq.gz Fastqsanger.gz
SRR11579384.fastq.gz Fastqsanger.gz
SRR11579385.fastq.gz Fastqsanger.gz
Items per page:
1 - 4 of 4

Similar Datasets

Genomics ChIP-Seq for FOXA1 in LNCaP cell line with GSK treatment and VEH control
| PRJNA627125 | ENA
Genomics ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control
| PRJNA627124 | ENA
Genomics ATAC-Seq in LNCaP cell line with GSK treatment and VEH control
2020-07-14 | GSE148925 | GEO
Genomics ChIP-Seq for FOXA2 in PC3 cell line with GSK treatment and VEH control
| PRJNA627123 | ENA
Genomics ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control
2020-07-14 | GSE148928 | GEO
Genomics ChIP-Seq for FOXA1 in LNCaP cell line with GSK treatment and VEH control
2020-07-14 | GSE148926 | GEO
Genomics GSK-inhibitor treatment in IMR32 neuroblastoma cell line
| PRJEB4227 | ENA
Transcriptomics GSK-3 inhibitor treatment effect on MLL leukemia cell
2010-05-27 | E-GEOD-19736 | biostudies-arrayexpress
Genomics Chromatin accessibility profiling by ATAC-seq in LNCaP-shNT and LNCaP-shTP53 cells
| PRJNA1073002 | ENA
Transcriptomics GSK-3 inhibitor treatment effect on MLL leukemia cell
2010-05-01 | GSE19736 | GEO